In vitro Matrigel Screening assay

• High throughput format analyzing angiogenesis inhibition or stimulation effects of drug modalities.

• HUVEC cells are plated in 96-well plates, treated with the molecules of interest and the cells are fixed on Day 1 for image and data analysis.

PROS:

• Screening assay at single or multiple concentrations (>100 molecules)
• Shorter timelines
• Species cross reactivity not a necessity

In vitro Matrigel co-culture screening and functional assay

• High and medium throughput format analyzing angiogenesis inhibition or stimulation effects of drug modalities.

• HUVEC and Human Dermal Fibroblast(HDF) cells are plated in 96-well or 24-well plates, treated with the molecules of interest every alternate day and the cells are fixed on Day 14 for image and data analysis.

PROS:

• Shorter to medium timelines (25-40 days from start of assay to final report)

• Two human cell types involved therefore gives features translatable to human angiogenesis

• Species cross reactivity not a necessity

• In vivo efficacy assay using wild type or diabetic rat/mice to analyze angiogenesis inhibition or stimulation effects of drug modalities

• Assay allows for eye-to-eye or animal-to-animal control

• In vivo Flouroscien Fundus Angiography (FFA) for early and late stage leakage of vessels is analyzed

• Optical CoherenceTomography analysis of lesions for retinal oedema for Diabetic animals (PDR) 

PROS:

• Enables analysis of function blocking or stimulating effects of molecules at multiple concentrations generating dose-response curve (1-15 molecules)

• Disease model offering transability to patients

• Combination therapy possible

• Lead identification assay

In vitro Matrigel co-culture screening and functional assay

• High and medium throughput format analyzing angiogenesis inhibition or stimulation effects of drug modalities.

• HUVEC and Human Dermal Fibroblast(HDF) cells are plated in 96-well or 24-well plates, treated with the molecules of interest every alternate day and the cells are fixed on Day 14 for image and data analysis.

PROS:

• Shorter to medium timelines (25-40 days from start of assay to final report)

• Two human cell types involved therefore gives features translatable to human angiogenesis

• Species cross reactivity not a necessity